FDA Clearance Tracker · P150013
PD-L1 IHC 22C3 PHARMDX
Last checked: Nov 20, 2026Latest source record: Oct 2, 2015 (this decision)Source: openFDAMethods & limitations
Decided
Oct 2, 2015
Approved
Time to decision
179 days
Received Apr 6, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P150013
- Device name
- PD-L1 IHC 22C3 PHARMDX
- Applicant
- Agilent Technologies, Inc.
- Applicant location
- Santa Clara, CA
- Received
- Apr 6, 2015
- Decided
- Oct 2, 2015
- Decision
- Approved
- Expedited review
- Yes, flagged as expedited in FDA's record.
- Supplements
- 35 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE PD-L1 IHC 22C3 PHARMDX. THIS DEVICE IS INDICATED FOR THE FOLLOWING: PD-L1 IHC 22C3 PHARMDX IS A QUALITATIVE IMMUNOHISTOCHEMICAL ASSAY USING MONOCLONAL MOUSE ANTI-PD-L1, CLONE 22C3 ANTIBODY INTENDED FOR USE IN THE DETECTION OF PD-L1PROTEIN IN FORMALIN FIXED, PARAFFIN EMBEDDED (FFPE) NON-SMALL CELL LUNG CANCER (NSCLC) TISSUE USING ENVISION FLEX VISUALIZATION SYSTEM ON AUTOSTAINER LINK 48. PD-L1 PROTEIN EXPRESSION IS DETERMINED BY USING TUMOR PROPORTION SCORE (TPS), WHICH IS THE PERCENTAGE OF VIABLE TUMOR CELLS SHOWING PARTIAL OR COMPLETE MEMBRANE STAINING. THE SPECIMEN SHOULD BE CONSIDERED PD-L1 POSITIVE IF TPS >= 50% OF THE VIABLE TUMOR CELLS EXHIBIT MEMBRANE STAINING AT ANY INTENSITY. PD-L1 IHC 22C3 PHARMDX IS INDICATED AS AN AID IN IDENTIFYING NSCLC PATIENTS FOR TREATMENT WITH KEYTRUDA (PEMBROLIZUMAB).
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code PLS (Immunohistochemistry assay, antibody, programmed death-ligand 1).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Agilent Technologies, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PD-L1 IHC 28-8 pharmDxPMA supplement
P150025-S018 · Decided Jul 1, 2026 · 180 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
- PD-L1 IHC 22C3 pharmDxPMA supplement
P150013-S032 · Decided Feb 11, 2026 · 187 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
- PD-L1 IHC 22C3 pharmDxPMA supplement
P150013-S033 · Decided Feb 10, 2026 · 134 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.